Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

Nature Medicine

Volumn 7, Issue 5, 2001, Pages 625-629

  Stubbs, Andrew C ^a   Martin, Kathleen S ^a   Coeshott, Claire ^b   Skaates, Serena V ^b   Kuritzkes, Daniel R ^a   Bellgrau, Donald ^a,b   Franzusoff, Alex ^a,b   Duke, Richard C ^a,b   Wilson, Cara C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Ceres Pharmaceuticals Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VACCINE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TARGET CELL; VACCINATION; YEAST;

AIDS VACCINES; ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, CELLULAR; MICE; MICE, TRANSGENIC; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC;

EID: 0035031781     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/87974     Document Type: Article

References (24)

1. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-52 (1998).
2. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nature Cell Biol. 1, 362-368 (1999).
3. Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-8 (1998).
4. Yewdell, J.W., Norbury, C.C. & Bennink, J.R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73, 1-77 (1999).
5. Falo, L.D., Jr., Kovacsovics-Bankowski, W., Thompson, K. & Rock, K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med. 1, 649-53 (1995).
6. O'Hagan, D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 50, 1-10 (1998).
7. Williams, D.L. et al. Development of a water-soluble, sulfated (1,3) - D-glucan biological response modifier derived from Saccharomyces cerevisiae. Carbohydr. Res. 235, 247-57 (1992).
8. Rios-Hernandez, M., Dos-Santos, N.J., Silvia, C., Bello-Garciga, J.L. & Pedroso, M. Immunopharmacological studies of β-1,3-glucan. Arch. Med. Res. 25, 179-80 (1994).
9. McCabe, B.J. et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 55, 1741-7 (1995).
10. Brossart, P., Goldrath, A.W., Butz, E.A., Martin, S. & Bevan, M.J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158, 3270-6 (1997).
11. Cho, H.J. et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature Biotechnol. 18, 509-14 (2000).
12. Hogquist, K.A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27 (1994).
13. Murphy, K.M., Heimberger, A.B. & Loh, D.Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRIo thymocytes in viva. Science 250, 1720-3 (1990).
14. Cella, M. et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-52 (1996).
15. Koch, F. et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184, 741-6 (1996).
16. De Smedt, T. et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. Exp. Med. 184, 1413-24 (1996).
17. Roake, J.A. et al. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181, 2237-47 (1995).
18. Franzusoff, A., Volpe, A.M., Josse, D., Pichuantes, S. & Wolf, J.R. Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing. J. Biol. Chem. 270, 3154-9 (1995).
19. Schreuder, M.P., Deen, C., Boersma, W.J., Pouwels, P.H. & Klis, F.M. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 14, 383-8 (1996).
20. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokinesand bacterial products. J. Exp. Med. 182, 389-400 (1995).
21. Toda, S. et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 92, 111-7 (1997).
22. Shibata, Y., Metzger, W.J. & Myrvik, Q.N. Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates 11-12 production. J. Immunol. 159, 2462-7 (1997).
23. Inaba, K. et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188, 2163-73 (1998).
24. Mayordomo, J.I. et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357-65 (1996).